Clinical Trials on Skin Diseases, Papulosquamous

Total 377126 results

Assiut University

Unknown

Climatotherapy Versus Topical Combination of Corticosteroids and Salicylic Acid in Treatment of Psoriasis

Papulosquamous Skin Disease
Fondazione Policlinico Universitario Agostino Gemelli...

Not yet recruiting

Evaluation of Tolerability, Efficacy and Adherence to Treatment With Wynzora Cream (psowyn)

Psoriasis
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

A Clinical Study of TQH2929 in Healthy Adult Subjects

Psoriasis

China
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Impact of Clinical and Psychological Factors on Treatment Satisfaction in Psoriatic Patients in Biological Therapy (PsoSAT)

Psoriasis

Italy
Wake Forest University Health Sciences
Amgen

Not yet recruiting

Adherence to Otezla

Psoriasis

United States
Wake Forest University Health Sciences
Bristol-Myers Squibb

Recruiting

Deucravacitinib Adherence Study

Psoriasis

United States
Centre Hospitalier Universitaire de Nice

Recruiting

Role of Glucose Metabolism in Migration of Cutaneous Dendritic Cells in Psoriasis

Psoriasis

France
University Hospitals Cleveland Medical Center
Case Western Reserve University; LEO Foundation

Recruiting

Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics

Psoriasis

United States
University of Athens

Recruiting

The Effect of Dietary Intervention on Endothelial Glycocalyx in Psoriasis

Psoriasis

Greece
Weill Medical College of Cornell University
Pfizer

Recruiting

Rimegepant in Moderate Plaque-type Psoriasis

Psoriasis

United States
Second Affiliated Hospital, School of Medicine,...

Recruiting

Chinese Psoriasis Real World Evidence Research

Psoriasis

China
Bausch Health Americas, Inc.

Recruiting

A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis

Psoriasis

United States, Panama
UNION therapeutics

Completed

Study to Assess the Efficacy and Safety of Orismilast in Psoriasis (IASOS)

Skin Diseases | Psoriasis

United Kingdom, Poland, United States, Germany
Psoriasis Treatment Center of Central New Jersey
Celgene Corporation

Completed

Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis

Psoriasis

United States
Psoriasis Treatment Center of Central New Jersey
Taro Pharmaceuticals USA

Completed

Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray

Psoriasis

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants

Psoriasis

Canada, Poland
AbbVie

Active, not recruiting

A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms (OptIMMize-1)

Psoriasis

United States, Canada, Germany, Japan, Poland, Spain, United Kingdom
Primus Pharmaceuticals
Prosoft Clinical

Completed

A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis

Psoriasis

United States
Tianjin Hemay Pharmaceutical Co., Ltd

Completed

Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects (Hemay005)

Psoriasis

China
Amgen

Completed

An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis (DISCREET)

Psoriasis

United States, Belgium, Italy, France, Germany, Puerto Rico, Canada
LEO Pharma

Terminated

Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis (EMBRACE 1)

Psoriasis

Belgium, Germany, Italy, Poland, Spain, France, Greece, Hungary
Bausch Health Americas, Inc.

Enrolling by invitation

LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis

Psoriasis

United States
Amgen

Active, not recruiting

A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

Psoriasis

Belgium, Spain, United States, Czechia, Italy, Russian Federation, Canada, France, Israel
Wake Forest University Health Sciences

Active, not recruiting

Assessing Patient Confidence in Biologic Medications

Psoriasis

United States
Wake Forest University Health Sciences

Active, not recruiting

A Priming Intervention to Increase Patient Willingness to Use Injectables for the Management of Psoriasis

Psoriasis

United States
Ventyx Biosciences, Inc

Terminated

VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis (Serenity PsO)

Psoriasis

Poland, United States, Canada
Wake Forest University Health Sciences
Pfizer

Completed

Oral Psoriasis Treatment Adherence and Intervention Study

Psoriasis

United States
Amgen

Terminated

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

Psoriasis

United States, Belgium, Spain, Czechia, Canada, Italy, Israel, France, Netherlands, Russian Federation
University of Southern California
Icahn School of Medicine at Mount Sinai; Brigham and Women's Hospital

Active, not recruiting

Validation of a Dermatology-Specific Treatment Satisfaction Instrument

Psoriasis

United States
Eli Lilly and Company

Completed

A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis

Psoriasis

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

Psoriasis

China
Assistance Publique Hopitaux De Marseille

Active, not recruiting

Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis (METHOBIO)

Psoriasis

France
Bispebjerg Hospital

Completed

Efficacy of Roflumilast in the Treatment of Psoriasis (PSORRO)

Psoriasis

Denmark
TC Erciyes University
Monitor CRO

Completed

Phase I Study of GN-037 Cream for Psoriasis

Psoriasis

Turkey
AbbVie

Completed

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Psoriasis

United States, Canada, Germany, Israel, Poland
Maruho Co., Ltd.

Withdrawn

A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With Plaque Psoriasis

Psoriasis
AbbVie

Enrolling by invitation

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 (OptIMMize-2)

Psoriasis

United States, Canada, Germany, Japan, Poland, Spain, United Kingdom
University Hospital, Ghent
KU Leuven

Completed

A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients Who Are Overtreated

Psoriasis

Belgium
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis (POETYK-PSO-2)

Psoriasis

United States, Spain, Hungary, Australia, Germany, Canada, Czechia, Poland, Puerto Rico, Finland, France, Israel, Italy, New Zealand, Sweden, United Kingdom
AbbVie

Withdrawn

Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting

Psoriasis
Boehringer Ingelheim

Terminated

A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is

Psoriasis

United States, Canada, Germany
Novartis Pharmaceuticals

Completed

Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis

Psoriasis

United States
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea (POETYK-PSO-3)

Psoriasis

China, Korea, Republic of, Taiwan
PharmaEssentia
Athenex, Inc.

Completed

KX01 Ointment Phase 1 Study in Patients With Plaque Type Psoriasis

Psoriasis
Galderma R&D

Completed

Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis

Psoriasis

United States
Galderma R&D

Completed

Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis

Psoriasis

United States, Canada
Akeso

Completed

A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis

Psoriasis

China
EMS

Withdrawn

Proton Pump Inhibitors Use in Patients With Psoriasis

Psoriasis
Galderma R&D

Completed

Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis

Psoriasis

United States
University of Michigan

Completed

The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis

Psoriasis

United States

3

Subscribe